Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Swiss biopharmaceutical company Basilea Pharmaceutica has received approval from the German health authority Bundesinstitut fur Arzneimittel und Medizinprodukte for Toctino, a new once-daily oral treatment for adults with severe chronic hand eczema unresponsive to potent topical corticosteroids.
Subscribe to our email newsletter
Following the recommendation for regulatory approval under the European decentralized procedure, Toctino (alitretinoin) received national regulatory approval in Germany.
Marketing applications for the use of alitretinoin in the treatment of severe chronic refractory hand eczema are also under regulatory review in Canada and in Switzerland.